Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Masimo (Nasdaq: MASI) agreed to be acquired by Danaher (NYSE: DHR) for $180.00 per share in cash, representing total consideration of $9.9 billion. The boards of both companies unanimously approved the transaction.
Masimo will operate as a standalone business unit and brand within Danaher’s Diagnostics segment and is expected to close in the second half of 2026, subject to regulatory approvals. Masimo will report Q4 and full‑year 2025 results on Feb 26, 2026 but will not host an earnings call.
Danaher (NYSE: DHR) entered a definitive agreement to acquire Masimo (NASDAQ: MASI) for $180 per share in cash, implying an approximate $9.9 billion enterprise value including assumed debt and net of cash. The deal values Masimo at ~18x estimated 2027 EBITDA (15x including expected synergies).
Danaher expects Masimo to generate >$530 million EBITDA in 2027, deliver >$125 million annual cost synergies and >$50 million annual revenue synergies by year five, and be accretive to adjusted diluted EPS by $0.15–$0.20 in year one and ~ $0.70 in year five. Closing is anticipated in H2 2026, subject to regulatory clearances and Masimo shareholder approval.
Danaher (NYSE: DHR) reported Q4 2025 net earnings of $1.2 billion ($1.66 per diluted share) and full‑year net earnings of $3.6 billion ($5.03 per diluted share).
Q4 revenue rose 4.5% to $6.8 billion; FY2025 revenue was $24.6 billion (+3.0%). Non‑GAAP adjusted EPS grew ~4% Q4 and 4.5% FY. Operating cash flow was $2.1 billion in Q4 and $6.4 billion for FY; non‑GAAP free cash flow was $1.8 billion Q4 and $5.3 billion FY.
The company launched new products across bioprocessing, mass spectrometry, and diagnostics and initiated FY2026 guidance: core revenue +3–6% and adjusted EPS $8.35–8.50.
Danaher (NYSE: DHR) announced that CEO Rainer M. Blair will comment on fourth quarter 2025 results at the J.P. Morgan Healthcare Conference on Jan 13, 2026 at 11:15 a.m. PT, with the presentation webcast on the company's Investors site.
For Q4 2025, Danaher expects estimated revenues to increase in the mid-single digit percent range year-over-year and non-GAAP core revenue growth toward the high end of its prior low-single digit guidance. For full-year 2025, the company expects non-GAAP adjusted diluted EPS toward the high end of its guidance range of $7.70 to $7.80. The company reiterated strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in Q4.
Danaher (NYSE: DHR) said its President and Chief Executive Officer, Rainer M. Blair, will present at the J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 11:15 a.m. PT.
The presentation will be simultaneously webcast and accessible from the company's Investors site under Events & Presentations at www.danaher.com.
Danaher (NYSE: DHR) will webcast its Fourth Quarter 2025 earnings conference call on Wednesday, January 28, 2026 at 8:00 a.m. ET, with an expected duration of about one hour.
The company will discuss financial performance and future expectations. The live webcast and accompanying slide presentation will be available in the Investors > Events & Presentations section at www.danaher.com. Webcast slides, the earnings press release, and related materials will be posted beginning at 6:00 a.m. ET on the day of the call.
Dial-in access: 800-245-3047 (U.S.) or +1 203-518-9765 (outside U.S.); Conference ID: DHRQ425. A replay of the webcast and call will be available after the presentation; the call replay remains available until February 11, 2026.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.32 per share. The dividend is payable on January 30, 2026 to holders of record on December 26, 2025.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 11:00 a.m. GMT.
The event will be simultaneously webcast and accessible via www.danaher.com, allowing investors and analysts to view the presentation live.
Danaher (NYSE: DHR) reported third quarter 2025 results for the period ended September 26, 2025. Revenue rose 4.5% YoY to $6.1B and non-GAAP core revenue increased 3.0% YoY. Net earnings were $908M, or $1.27 per diluted share; adjusted diluted EPS was $1.89. Operating cash flow was $1.7B and non-GAAP free cash flow was $1.4B. The company maintained full‑year 2025 adjusted diluted EPS guidance of $7.70–$7.80 and expects non‑GAAP core revenue to grow in the low‑single digits for 2025. Management highlighted bioprocessing momentum and stronger respiratory revenue at Cepheid. The company disclosed estimated 2025 acquisition amortization of $1.7B and an estimated +1.0% FX sales impact for the full year.
Danaher (NYSE:DHR) has scheduled its Q3 2025 earnings conference call for October 21, 2025 at 8:00 a.m. ET. The one-hour call will include discussions on financial performance and future outlook. The presentation will be accessible via webcast on Danaher's website under the "Investors" section.
Participants can join by dialing 800-245-3047 (U.S.) or +1 203-518-9765 (international). The earnings materials, including press release, slides, Form 10-Q, and non-GAAP reconciliations, will be available on the company's website at 6:00 a.m. ET on the call date. A replay will be available until November 4, 2025.